Locations:
SearchAdvertisement
Interim results of phase 2 trial are promising
How to care for patients with this rare, complex disease
Study explores atezolizumab for myelodysplastic syndrome
Second (or third) time’s a charm in reducing splenomegaly and other symptoms
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
How one hematologist learned to use and value it
Final results of PERSIST-2 confirm benefit; PAC203 enrolling
An oncologist weighs in
JAK inhibitors, the hedgehog pathway and answers for anemia
Advertisement
Advertisement